Three approvals were for new products, including Shire’s dry eye treatment.
Both implants are in the final stages of FDA review.
Country faces myopia rate of more than 50 percent in four years, based on current trends.
Deal calls for $225 million up front, plus milestone payments.
California accelerator outgrows conference venue and promises larger space in 2017.
The lens was launched at the 2014 ESCRS convention, and its popularity has grown.
Allergan’s Restasis, previously the only prescription dry eye drug in the US, posted revenues of more than $1 billion in 2015.
The company plans to launch the device in Q3-2016.
The drug was first approved in the US in 2003 for rheumatoid arthritis and has been used to treat more than 989 thousand patients worldwide, the company said.
The platform was approved in April for treatment of progressive keratoconus.
Waltham, MA-based BVI makes ophthalmic surgical instruments for cataract, refractive, oculoplastic, and vitreoretinal procedures.
The combined company, to be named Envision Healthcare Corporation, will have a market cap of about $10 billion
Longtime board member Reinhard Rubow will become executive director.
Ophthalmic industry veteran started in the role June 12.
Nominees may be submitted through Aug. 31.
Alcon’s AcrySof IQ ReSTOR multifocal toric lens has been waiting the longest, receiving the backing of an FDA advisory panel in November 2014.
Manufacturing deficiencies were the focus of concerns, not the performance of the drug.
Trade group representing ASCs said it hopes health officials have dropped the idea.
Twenty-four of 30 patients had functioning implants midway through the 10-year trial.
Boston startup said it will add service this fall in Chicago.
The partnership was announced July 5, shortly after IBM Watson unveiled its own AI project in eye care.
The Pennsylvania ophthalmologist was making a monthly trip to State College to perform surgery.
You are not currently logged in.
©2017 Market Scope
Lost your Password